Search

Your search keyword '"Fife, Kate"' showing total 201 results
Start Over Author "Fife, Kate"
201 results on '"Fife, Kate"'

1. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

Author

Stewart, Grant D., Welsh, Sarah J., Ursprung, Stephan, Gallagher, Ferdia A., Jones, James O., Shields, Jacqui, Smith, Christopher G., Mitchell, Thomas J., Warren, Anne Y., Bex, Axel, Boleti, Ekaterini, Carruthers, Jade, Eisen, Tim, Fife, Kate, Hamid, Abdel, Laird, Alexander, Leung, Steve, Malik, Jahangeer, Mendichovszky, Iosif A., Mumtaz, Faiz, Oades, Grenville, Priest, Andrew N., Riddick, Antony C. P., Venugopal, Balaji, Welsh, Michelle, Riddle, Kathleen, Hopcroft, Lisa E. M., and Jones, Robert J.

Published
2022
Full Text
View/download PDF

3. Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy

Author

Hall, Peter E., Shepherd, Scott T.C., Brown, Janet, Larkin, James, Jones, Robert, Ralph, Christy, Hawkins, Robert, Chowdhury, Simon, Boleti, Ekaterini, Bahl, Amit, Fife, Kate, Webb, Andrew, Crabb, Simon J., Geldart, Thomas, Hill, Robert, Dunlop, Joanna, McLaren, Duncan, Ackerman, Charlotte, Wimalasingham, Akhila, Beltran, Luis, Nathan, Paul, and Powles, Thomas

Published
2020
Full Text
View/download PDF

4. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Author

Ursprung, Stephan, Mossop, Helen, Gallagher, Ferdia A., Sala, Evis, Skells, Richard, Sipple, Jamal A. N., Mitchell, Thomas J., Chhabra, Anita, Fife, Kate, Matakidou, Athena, Young, Gemma, Walker, Amanda, Thomas, Martin G., Ortuzar, Mireia Crispin, Sullivan, Mark, Protheroe, Andrew, Oades, Grenville, Venugopal, Balaji, Warren, Anne Y., Stone, John, Eisen, Tim, Wason, James, Welsh, Sarah J., and Stewart, Grant D.

Published
2021
Full Text
View/download PDF

5. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

Author

Vasudev, Naveen S., primary, Ainsworth, Gemma, additional, Brown, Sarah, additional, Pickering, Lisa, additional, Waddell, Tom, additional, Fife, Kate, additional, Griffiths, Richard, additional, Sharma, Anand, additional, Katona, Eszter, additional, Howard, Helen, additional, Velikova, Galina, additional, Maraveyas, Anthony, additional, Brown, Janet, additional, Pezaro, Carmel, additional, Tuthill, Mark, additional, Boleti, Ekaterini, additional, Bahl, Amit, additional, Szabados, Bernadett, additional, Banks, Rosamonde E., additional, Brown, Joanne, additional, Venugopal, Balaji, additional, Patel, Poulam, additional, Jain, Ankit, additional, Symeonides, Stefan N., additional, Nathan, Paul, additional, Collinson, Fiona J., additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

9. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Author

Colomba, Emeline, Le Teuff, Gwénaël, Eisen, Tim, Stewart, Grant D., Fife, Kate, Larkin, James, Biondo, Andrea, Pickering, Lisa, Srinivasan, Anandagopal, Boyle, Helen, Derosa, Lisa, Sternberg, Cora N., Recine, Federica, Ralph, Christy, Saldana, Carolina, Barthélémy, Philippe, Bernhard, Jean Christophe, Gurney, Howard, Verhoest, Gregory, Vauleon, Elodie, Bigot, Pierre, Berger, Julien, Pfister, Christian, Gravis, Gwenaelle, Rodier, Jean-Michel, Culine, Stéphane, Caty, Armelle, Rolland, Frederic, Priou, Franck, Escudier, Bernard, and Albiges, Laurence

Published
2017
Full Text
View/download PDF

11. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

Author

Vasudev, Naveen S., Ainsworth, Gemma, Brown, Sarah, Pickering, Lisa, Waddell, Tom, Fife, Kate, Griffiths, Richard, Sharma, Anand, Katona, Eszter, Howard, Helen, Velikova, Galina, Maraveyas, Anthony, Brown, Janet, Pezaro, Carmel, Tuthill, Mark, Boleti, Ekaterini, Bahl, Amit, Szabados, Bernadett, Banks, Rosamonde E., and Brown, Joanne

Published
2024
Full Text
View/download PDF

12. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma

Author

Marconi, Lorenzo, de Bruijn, Roderick, van Werkhoven, Erik, Beisland, Christian, Fife, Kate, Heidenreich, Axel, Kapoor, Anil, Karam, Jose, Kauffmann, Caroline, Klatte, Tobias, Ljungberg, Boerje, Matin, Surena, Sjoberg, Daniel, Staehler, Michael, Stewart, Grant D., Tanguay, Simon, Uzzo, Robert, Welsh, Sarah, Wood, Lori, Wood, Chris, and Bex, Axel

Published
2018
Full Text
View/download PDF

14. Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site

Author

Fowler, Joanna C., primary, King, Charlotte, primary, Bryant, Christopher, primary, Hall, Michael W.J., primary, Sood, Roshan, primary, Ong, Swee Hoe, primary, Earp, Eleanor, primary, Fernandez-Antoran, David, primary, Koeppel, Jonas, primary, Dentro, Stefan C., primary, Shorthouse, David, primary, Durrani, Amer, primary, Fife, Kate, primary, Rytina, Edward, primary, Milne, Doreen, primary, Roshan, Amit, primary, Mahububani, Krishnaa, primary, Saeb-Parsy, Kourosh, primary, Hall, Benjamin A., primary, Gerstung, Moritz, primary, and Jones, Philip H., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site

Author

Fowler, Joanna C., primary, King, Charlotte, primary, Bryant, Christopher, primary, Hall, Michael W.J., primary, Sood, Roshan, primary, Ong, Swee Hoe, primary, Earp, Eleanor, primary, Fernandez-Antoran, David, primary, Koeppel, Jonas, primary, Dentro, Stefan C., primary, Shorthouse, David, primary, Durrani, Amer, primary, Fife, Kate, primary, Rytina, Edward, primary, Milne, Doreen, primary, Roshan, Amit, primary, Mahububani, Krishnaa, primary, Saeb-Parsy, Kourosh, primary, Hall, Benjamin A., primary, Gerstung, Moritz, primary, and Jones, Philip H., primary

Published
2023
Full Text
View/download PDF

16. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Author

Buckley, Hannah L., Collinson, Fiona J., Ainsworth, Gemma, Poad, Heather, Flanagan, Louise, Katona, Eszter, Howard, Helen C., Murden, Geraldine, Banks, Rosamonde E., Brown, Joanne, Velikova, Galina, Waddell, Tom, Fife, Kate, Nathan, Paul D., Larkin, James, Powles, Thomas, Brown, Sarah R., and Vasudev, Naveen S.

Published
2019
Full Text
View/download PDF

17. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort

Author

Klatte, Tobias, Gallagher, Kevin M., Afferi, Luca, Volpe, Alessandro, Kroeger, Nils, Ribback, Silvia, McNeill, Alan, Riddick, Antony C. P., Armitage, James N., ‘Aho, Tevita F., Eisen, Tim, Fife, Kate, Bex, Axel, Pantuck, Allan J., and Stewart, Grant D.

Published
2019
Full Text
View/download PDF

18. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib

Author

Welsh, Sarah J, Thompson, Nicola, Warren, Anne, Priest, Andrew N, Barrett, Tristan, Ursprung, Stephan, Gallagher, Ferdia A, Zaccagna, Fulvio, Stewart, Grant D, Fife, Kate M, Matakidou, Athena, Machin, Andrea J, Qian, Wendi, Ingleson, Victoria, Mullin, Jean, Riddick, Antony CP, Armitage, James N, Connolly, Stephen, Eisen, Timothy GQ, Welsh, Sarah J [0000-0001-5690-2677], Priest, Andrew N [0000-0002-9771-4290], Stewart, Grant D [0000-0003-3188-9140], Fife, Kate M [0000-0002-1880-9049], and Apollo - University of Cambridge Repository

Subjects
Necrosis, renal cell carcinoma, Indoles, sunitinib, Vascular Endothelial Growth Factor C, nephrectomy, Humans, Pyrroles, Antineoplastic Agents, neoadjuvant therapy, Carcinoma, Renal Cell, Biomarkers, Kidney Neoplasms
Abstract

Funder: Pfizer; Id: http://dx.doi.org/10.13039/100004319, OBJECTIVE: To explore translational biological and imaging biomarkers for sunitinib treatment before and after debulking nephrectomy in the NeoSun (European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] number: 2005-004502-82) single-centre, single-arm, single-agent, Phase II trial. PATIENTS AND METHODS: Treatment-naïve patients with metastatic renal cell carcinoma (mRCC) received 50 mg once daily sunitinib for 12 days pre-surgically, then post-surgery on 4 week-on, 2 week-off, repeating 6-week cycles until disease progression in a single arm phase II trial. Structural and dynamic contrast-enhanced magnet resonance imaging (DCE-MRI) and research blood sampling were performed at baseline and after 12 days. Computed tomography imaging was performed at baseline and post-surgery then every two cycles. The primary endpoint was objective response rate (Response Evaluation Criteria In Solid Tumors [RECIST]) excluding the resected kidney. Secondary endpoints included changes in DCE-MRI of the tumour following pre-surgery sunitinib, overall survival (OS), progression-free survival (PFS), response duration, surgical morbidity/mortality, and toxicity. Translational and imaging endpoints were exploratory. RESULTS: A total of 14 patients received pre-surgery sunitinib, 71% (10/14) took the planned 12 doses. All underwent nephrectomy, and 13 recommenced sunitinib postoperatively. In all, 58.3% (seven of 12) of patients achieved partial or complete response (PR or CR) (95% confidence interval 27.7-84.8%). The median OS was 33.7 months and median PFS was 15.7 months. Amongst those achieving a PR or CR, the median response duration was 8.7 months. No unexpected surgical complications, sunitinib-related toxicities, or surgical delays occurred. Within the translational endpoints, pre-surgical sunitinib significantly increased necrosis, and reduced cluster of differentiation-31 (CD31), Ki67, circulating vascular endothelial growth factor-C (VEGF-C), and transfer constant (KTrans , measured using DCE-MRI; all P < 0.05). There was a trend for improved OS in patients with high baseline plasma VEGF-C expression (P = 0.02). Reduction in radiological tumour volume after pre-surgical sunitinib correlated with high percentage of solid tumour components at baseline (Spearman's coefficient ρ = 0.69, P = 0.02). Conversely, the percentage tumour volume reduction correlated with lower baseline percentage necrosis (coefficient = -0.51, P = 0.03). CONCLUSION: Neoadjuvant studies such as the NeoSun can safely and effectively explore translational biological and imaging endpoints.

Published
2022

20. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

Author

Basset-Seguin, Nicole, Hauschild, Axel, Grob, Jean-Jacques, Kunstfeld, Rainer, Dréno, Brigitte, Mortier, Laurent, Ascierto, Paolo A, Licitra, Lisa, Dutriaux, Caroline, Thomas, Luc, Jouary, Thomas, Meyer, Nicolas, Guillot, Bernard, Dummer, Reinhard, Fife, Kate, Ernst, D Scott, Williams, Sarah, Fittipaldo, Alberto, Xynos, Ioannis, and Hansson, Johan

Published
2015
Full Text
View/download PDF

23. Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib

Author

Welsh, Sarah J., primary, Thompson, Nicola, additional, Warren, Anne, additional, Priest, Andrew N., additional, Barrett, Tristan, additional, Ursprung, Stephan, additional, Gallagher, Ferdia A., additional, Zaccagna, Fulvio, additional, Stewart, Grant D., additional, Fife, Kate M., additional, Matakidou, Athena, additional, Machin, Andrea J., additional, Qian, Wendi, additional, Ingleson, Victoria, additional, Mullin, Jean, additional, Riddick, Antony C. P., additional, Armitage, James N., additional, Connolly, Stephen, additional, and Eisen, Timothy G. Q., additional

Published
2021
Full Text
View/download PDF

25. Additional file 3 of The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer ��� a study protocol

Author

Ursprung, Stephan, Mossop, Helen, Gallagher, Ferdia A., Sala, Evis, Skells, Richard, Sipple, Jamal A. N., Mitchell, Thomas J., Chhabra, Anita, Fife, Kate, Matakidou, Athena, Young, Gemma, Walker, Amanda, Thomas, Martin G., Ortuzar, Mireia Crispin, Sullivan, Mark, Protheroe, Andrew, Oades, Grenville, Venugopal, Balaji, Warren, Anne Y., Stone, John, Eisen, Tim, Wason, James, Welsh, Sarah J., and Stewart, Grant D.

Subjects
Data_FILES
Abstract

Additional file 3.

Published
2021
Full Text
View/download PDF

26. Additional file 2 of The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer ��� a study protocol

Author

Ursprung, Stephan, Mossop, Helen, Gallagher, Ferdia A., Sala, Evis, Skells, Richard, Sipple, Jamal A. N., Mitchell, Thomas J., Chhabra, Anita, Fife, Kate, Matakidou, Athena, Young, Gemma, Walker, Amanda, Thomas, Martin G., Ortuzar, Mireia Crispin, Sullivan, Mark, Protheroe, Andrew, Oades, Grenville, Venugopal, Balaji, Warren, Anne Y., Stone, John, Eisen, Tim, Wason, James, Welsh, Sarah J., and Stewart, Grant D.

Subjects
Data_FILES
Abstract

Additional file 2.

Published
2021
Full Text
View/download PDF

28. British HIV Association guidelines for HIV-associated malignancies 2014

Author

Bower, Mark, Palfreeman, A, Alfa-Wali, Maryam, Bunker, Chris, Burns, Fiona, Churchill, Duncan, Collins, Simon, Cwynarski, Kate, Edwards, Simon, Fields, Paul, Fife, Kate, Gallop-Evans, Eve, Kassam, Shireen, Kulasegaram, Ranjababu, Lacey, Charles, Marcus, Robert, Montoto, Sylvia, Nelson, Mark, Newsom-Davis, Tom, Orkin, Chloe, Shaw, Kate, Tenant-Flowers, Melinda, Webb, Andrew, Westwell, Sarah, and Williams, Matt

Published
2014
Full Text
View/download PDF

30. Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.

Author

Corrie, Philippa Gail, primary, Welsh, Sarah Joanne, additional, Stewart, Grant D., additional, Doherty, Gary, additional, Vervier, Kevin, additional, Neville, Anne, additional, Parkinson, Christine, additional, Fife, Kate, additional, Faust, Guy, additional, Jayaprakash, Kamalram Thippu, additional, Geldart, Thomas R., additional, Brown, Ewan, additional, Wheater, Matthew, additional, Nobes, Jenny Penelope, additional, Bruce, David, additional, Demiris, Nikos, additional, Dalchau, Katy Marie, additional, Adams, David, additional, Robinson, Mat, additional, and Lawley, Trevor, additional

Published
2021
Full Text
View/download PDF

31. Real-world treatment patterns and overall survival in previously treated advanced renal cell carcinoma patients receiving nivolumab in the UK.

Author

Waddell, Tom, primary, Fife, Kate, additional, Griffiths, Richard, additional, Sharma, Anand, additional, Dhokia, Poonam, additional, Gordon, Jason, additional, Groves, Lara, additional, Hurst, Michael, additional, Sugrue, Daniel, additional, Tsang, Carmen, additional, Mckenna, Stephen, additional, Houghton, John, additional, and Carroll, Robert, additional

Published
2021
Full Text
View/download PDF

32. Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib.

Author

Welsh, Sarah J., Thompson, Nicola, Warren, Anne, Priest, Andrew N., Barrett, Tristan, Ursprung, Stephan, Gallagher, Ferdia A., Zaccagna, Fulvio, Stewart, Grant D., Fife, Kate M., Matakidou, Athena, Machin, Andrea J., Qian, Wendi, Ingleson, Victoria, Mullin, Jean, Riddick, Antony C. P., Armitage, James N., Connolly, Stephen, and Eisen, Timothy G. Q.

Subjects
CONTRAST-enhanced magnetic resonance imaging, SUNITINIB, RENAL cell carcinoma, COMPUTED tomography, SURGICAL complications, RANK correlation (Statistics)
Abstract

Objective: To explore translational biological and imaging biomarkers for sunitinib treatment before and after debulking nephrectomy in the NeoSun (European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] number: 2005‐004502‐82) single‐centre, single‐arm, single‐agent, Phase II trial. Patients and Methods: Treatment‐naïve patients with metastatic renal cell carcinoma (mRCC) received 50 mg once daily sunitinib for 12 days pre‐surgically, then post‐surgery on 4 week‐on, 2 week‐off, repeating 6‐week cycles until disease progression in a single arm phase II trial. Structural and dynamic contrast‐enhanced magnet resonance imaging (DCE‐MRI) and research blood sampling were performed at baseline and after 12 days. Computed tomography imaging was performed at baseline and post‐surgery then every two cycles. The primary endpoint was objective response rate (Response Evaluation Criteria In Solid Tumors [RECIST]) excluding the resected kidney. Secondary endpoints included changes in DCE‐MRI of the tumour following pre‐surgery sunitinib, overall survival (OS), progression‐free survival (PFS), response duration, surgical morbidity/mortality, and toxicity. Translational and imaging endpoints were exploratory. Results: A total of 14 patients received pre‐surgery sunitinib, 71% (10/14) took the planned 12 doses. All underwent nephrectomy, and 13 recommenced sunitinib postoperatively. In all, 58.3% (seven of 12) of patients achieved partial or complete response (PR or CR) (95% confidence interval 27.7–84.8%). The median OS was 33.7 months and median PFS was 15.7 months. Amongst those achieving a PR or CR, the median response duration was 8.7 months. No unexpected surgical complications, sunitinib‐related toxicities, or surgical delays occurred. Within the translational endpoints, pre‐surgical sunitinib significantly increased necrosis, and reduced cluster of differentiation‐31 (CD31), Ki67, circulating vascular endothelial growth factor‐C (VEGF‐C), and transfer constant (KTrans, measured using DCE‐MRI; all P < 0.05). There was a trend for improved OS in patients with high baseline plasma VEGF‐C expression (P = 0.02). Reduction in radiological tumour volume after pre‐surgical sunitinib correlated with high percentage of solid tumour components at baseline (Spearman's coefficient ρ = 0.69, P = 0.02). Conversely, the percentage tumour volume reduction correlated with lower baseline percentage necrosis (coefficient = −0.51, P = 0.03). Conclusion: Neoadjuvant studies such as the NeoSun can safely and effectively explore translational biological and imaging endpoints. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Additional file 1 of Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Author

Hawkins, Robert, Fife, Kate, Hurst, Michael, Wang, Meng, Niroshini Naicker, Nolasco, Sarah, Eisen, Tim, Matakidou, Athena, and Gordon, Jason

Abstract

Additional file 1: Supplementary Table 1. Time-to-events by LOT. Supplementary Table 2. Adverse events by LOT. Supplementary Figure 1. Treatment pathways for patients receiving systemic therapies. Supplementary Figure 2. Overall survival from 2LOT stratified by key baseline characteristics. Supplementary Figure 3. Overall survival by LOT in patients receiving interleukin-2/interferon-alpha at any LOT

Published
2020
Full Text
View/download PDF

34. Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site

Author

Fowler, Joanna C., primary, King, Charlotte, additional, Bryant, Christopher, additional, Hall, Michael W.J., additional, Sood, Roshan, additional, Ong, Swee Hoe, additional, Earp, Eleanor, additional, Fernandez-Antoran, David, additional, Koeppel, Jonas, additional, Dentro, Stefan C., additional, Shorthouse, David, additional, Durrani, Amer, additional, Fife, Kate, additional, Rytina, Edward, additional, Milne, Doreen, additional, Roshan, Amit, additional, Mahububani, Krishnaa, additional, Saeb-Parsy, Kourosh, additional, Hall, Benjamin A., additional, Gerstung, Moritz, additional, and Jones, Philip H., additional

Published
2021
Full Text
View/download PDF

35. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Author

Motzer, Robert J., Hutson, Thomas E., Cella, David, Reeves, James, Hawkins, Robert, Guo, Jun, Nathan, Paul, Staehler, Michael, de Souza, Paul, Merchan, Jaime R., Boleti, Ekaterini, Fife, Kate, Jin, Jie, Jones, Robert, Uemura, Hirotsugu, De Giorgi, Ugo, Harmenberg, Ulrika, Wang, Jinwan, Sternberg, Cora N., Deen, Keith, McCann, Lauren, Hackshaw, Michelle D., Crescenzo, Rocco, Pandite, Lini N., and Choueiri, Toni K.

Published
2013
Full Text
View/download PDF

36. Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma

Author

Lawrence, Nicola J., primary, Martin, Andrew, additional, Davis, Ian D., additional, Troon, Simon, additional, Sengupta, Shomik, additional, Hovey, Elizabeth, additional, Coskinas, Xanthi, additional, Kaplan, Richard, additional, Smith, Benjamin, additional, Ritchie, Alastair W. S., additional, Meade, Angela, additional, Goh, Jeffrey, additional, Gurney, Howard, additional, Harrison, Michelle, additional, Fife, Kate, additional, Eisen, Tim, additional, Blinman, Prunella, additional, and Stockler, Martin R., additional

Published
2020
Full Text
View/download PDF

39. MOESM1 of PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Author

Buckley, Hannah, Collinson, Fiona, Ainsworth, Gemma, Poad, Heather, Flanagan, Louise, Katona, Eszter, Howard, Helen, Murden, Geraldine, Rosamonde Banks, Brown, Joanne, Velikova, Galina, Waddell, Tom, Fife, Kate, Nathan, Paul, Larkin, James, Powles, Thomas, Brown, Sarah, and Vasudev, Naveen

Abstract

Additional file 1: Table S1. SPIRIT Checklist.

Published
2019
Full Text
View/download PDF

40. MOESM6 of The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort

Author

Klatte, Tobias, Gallagher, Kevin, Afferi, Luca, Volpe, Alessandro, Kroeger, Nils, Ribback, Silvia, McNeill, Alan, Riddick, Antony, Armitage, James, Tevita ‘Aho, Eisen, Tim, Fife, Kate, Bex, Axel, Pantuck, Allan, and Stewart, Grant

Abstract

Additional file 6: Figure S6. cumulative incidence of disease recurrence of patients with PRCC recruited into ASSURE according to UISS, Leibovich Score 2018 and VENUSS group.

Published
2019
Full Text
View/download PDF

43. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

Author

Hansson, Johan, Bartley, Karen, Karagiannis, Thomas, Grob, Jean-Jacques, Kunstfeld, Rainer, Dreno, Brigitte, Mortier, Laurent, Ascierto, Paolo, Licitra, Lisa, Dutriaux, Caroline, Thomas, Luc, Meyer, Nicolas, Guillot, Bernard, Dummer, Reinhard, Fife, Kate, Ernst, D Scott, Yim, Yeun Mi, Dimier, Natalie, Fittipaldo, Alberto, Basset-Seguin, Nicole, Hauschild, Axel, Hôpital de la Timone [CHU - APHM] (TIMONE), Medizinische Universität Wien = Medical University of Vienna, Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), University hospital of Zurich [Zurich], Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Adult, Male, Skin Neoplasms, Time Factors, Adolescent, Pyridines, Emotions, Antineoplastic Agents, Hedgehog pathway inhibitor, STEVIE, HRQoL, Young Adult, basal cell carcinoma, Surveys and Questionnaires, locally advanced, vismodegib, Humans, Anilides, skin and connective tissue diseases, Aged, Aged, 80 and over, integumentary system, Middle Aged, Carcinoma, Basal Cell, Quality of Life, Female, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; Health-related quality of life (HRQoL) data are limited in patients with advanced basal cell carcinoma. To report HRQoL outcomes based on STEVIE (NCT01367665), a phase 2 study of vismodegib safety in patients with metastatic BCC or locally advanced BCC that is unsuitable for surgery or radiotherapy. Skindex-16 and MD Anderson Symptom Inventory (MDASI) questionnaires were completed at baseline and at three subsequent visits. Clinically meaningful improvement was defined as a ≥10-point decrease from baseline (Skindex-16) or improvement of at least 3 points from baseline (MDASI). HRQoL-evaluable patients with locally advanced BCC (n = 730) had ≥10-point improvements in Skindex-16 emotion domain scores at all time points. Changes in symptom and function scores in these patients or in any domain scores at any time point in patients with metastatic BCC (n = 10) were not clinically meaningful. Of 10 patients with symptomatic metastatic BCC at baseline, six had ≥3-point improvements in MDASI symptom severity. Skindex-16 and MDASI showed improvement in HRQoL in vismodegib-treated patients with locally advanced or metastatic BCC or BCC.

Published
2018
Full Text
View/download PDF

44. A feasibility study before a national randomised controlled trial (RCT) of radiotherapy (RT) in the treatment of patients with pT2 and pT3 (high risk) head and neck primary cutaneous squamous cell carcinoma (H&N pcSCC)

Author

Newlands, Carrie, primary, Thompson, Jason, additional, Proby, Charlotte, additional, Williams, Sian Lax, additional, Harwood, Catherine, additional, Fife, Kate, additional, Marsden, Jeremy, additional, and Rembliak, Agata, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results